Nat Prod Rep. 2012 Oct;29(10):1074-98. doi: 10.1039/c2np20025b. Epub 2012 Jul 17.
Many pharmaceuticals on the market today belong to a large class of natural products called nonribosomal peptides (NRPs). Originating from bacteria and fungi, these peptide-based natural products consist not only of the 20 canonical L-amino acids, but also non-proteinogenic amino acids, heterocyclic rings, sugars, and fatty acids, generating tremendous chemical diversity. As a result, these secondary metabolites exhibit a broad array of bioactivity, ranging from antimicrobial to anticancer. The biosynthesis of these complex compounds is carried out by large multimodular megaenzymes called nonribosomal peptide synthetases (NRPSs). Each module is responsible for incorporation of a monomeric unit into the natural product peptide and is composed of individual domains that perform different catalytic reactions. Biochemical and bioinformatic investigations of these enzymes have uncovered the key principles of NRP synthesis, expanding the pharmaceutical potential of their enzymatic processes. Progress has been made in the manipulation of this biosynthetic machinery to develop new chemoenzymatic approaches for synthesizing novel pharmaceutical agents with increased potency. This review focuses on the recent discoveries and breakthroughs in the structural elucidation, molecular mechanism, and chemical biology underlying the discrete domains within NRPSs.
目前市场上的许多药物都属于一类称为非核糖体肽 (NRP) 的天然产物。这些基于肽的天然产物源自细菌和真菌,不仅包含 20 种常见的 L-氨基酸,还包含非蛋白氨基酸、杂环、糖和脂肪酸,从而产生了巨大的化学多样性。因此,这些次级代谢产物表现出广泛的生物活性,从抗菌到抗癌不等。这些复杂化合物的生物合成是由称为非核糖体肽合成酶 (NRPS) 的大型多模块巨型酶完成的。每个模块负责将一个单体单元掺入天然产物肽中,由执行不同催化反应的单个结构域组成。对这些酶的生化和生物信息学研究揭示了 NRP 合成的关键原则,扩大了其酶促过程的药物潜力。在操纵这种生物合成机制以开发新的化学酶方法来合成具有更高效力的新型药物方面已经取得了进展。本文综述了 NRPS 中离散结构域的结构阐明、分子机制和化学生物学方面的最新发现和突破。